In previous research reports, DKK1 has been confirmed as a prognostic biomarker for various malignancies [25, 26], and it can well predict the efficacy and prognosis of TACE treatment in HCC patients [27]; however, NDRG1 was not confirmed in previous studies. This evidence concerns the gene NDRG1 and hepatocellular carcinoma.